QUESTIONS FOR YOUR EYE DOCTOR

1. How does diabetes affect diabetic macular edema (DME)?
2. Are there steps I can take to help slow the progression of DME?
3. How does recurring DME affect my vision?
4. What are my options for treating DME and improving my vision?
5. I have had diabetes for ___ year(s). Will this affect DME treatment types available to me?
6. How can I reduce the number of eye injections I currently receive?
7. How does ILUVIEN work?
8. Can I still get ILUVIEN even though I have another eye condition or prior eye surgery?
9. What is the procedure for administering ILUVIEN?
10. What type of payment or insurance coverage is available for ILUVIEN?
11. What are the risks and possible side effects associated with ILUVIEN?
12. What is my follow-up plan after an ILUVIEN injection?

Indication
ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.

Important Safety Information
Do not use ILUVIEN if you have or think you might have an infection in or around the eye.
ILUVIEN should not be used if you have advanced glaucoma.

You should not use ILUVIEN if you are allergic to any ingredients of ILUVIEN.
Injections into the vitreous in the eye are associated with a serious eye infection (endophthalmitis), eye inflammation, increased eye pressure, glaucoma, and retinal detachments. Your eye doctor should monitor you regularly after the injection.
Use of corticosteroids including ILUVIEN may produce cataracts (ILUVIEN 82%; sham 50%), increased eye pressure (ILUVIEN 34%; sham 10%), glaucoma, and may increase secondary eye infections due to bacteria, fungi, or viruses. Let your doctor know if you have a history of herpes viral infections of the eye.
If the posterior capsule of the lens of your eye is missing or torn the ILUVIEN implant may move to the front chamber of the eye.
The most common side effects reported in patients with diabetic macular edema who were treated with ILUVIEN include cataracts (ILUVIEN 82%; sham 50%) and increased eye pressure (ILUVIEN 34%; sham 10%).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

ILUVIEN is a registered trademark of Alimera Sciences, Inc.

Copyright ©2019 Alimera Sciences, Inc. All rights reserved.1-844-445-8843. Printed in USA. US-ILV-MMM-0753 09/2019